106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved
ASCOBUR7213b
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO® practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines do
not account for individual variation among patients. is pocket guide does not purport to suggest any
particular course of medical treatment. Use of the practice guidelines and this resource are voluntary.
e practice guidelines and additional information are available at www.asco.org/breast-cancer-
guidelines. Copyright © 2021 by American Society of Clinical Oncolog y. All rights reserved.
Abbreviations
AI, aromatase inhibitor; CDK, cyclin-dependent kinase; HER2, human epidermal growth
factor receptor2; HR, hormone receptor; OS, overall survival; PARP, poly-ribose polymerase;
PFS, progression-free survival; SERD, selective estrogen receptor degrader
Source
Burstein HJ et al. Endocrine Treatment and Targeted erapy for HR-Positive, HER2-
Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 July 29
doi: 10.1200/JCO.21.01392.
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-based B Benefits
outweigh
harms
H High Strong
CB/
FC
Consensus-
based/Formal
Consensus
H Harms
outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative
balance of
benefits
and harms
L Low Weak
N No
recommendation
U Benefits/
harms
ratio
uncertain
Ins Insufficient
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/breast-cancer-guidelines.